News | December 05, 2021
Monthly production capacity of Covishield and Covaxin touches 90% : Govt
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
